Liuwei Dihuang Formula Ameliorates Aberrant Cholesterol Metabolism in Postmenopausal APOE-/- Mice by Regulating Intestinal Microbiota and Bile Acid Metabolism
-
摘要:
目的 探究六味地黄方调节肠道菌群和胆汁酸代谢改善小鼠绝经后胆固醇代谢异常及可能的作用机制。 方法 利用双侧卵巢摘除的APOE-/-小鼠给予高脂饮食, 复制绝经后胆固醇代谢异常模型, 并给予0.13 mg·kg-1的雌二醇和9.0 g·kg-1的六味地黄方进行治疗。90 d治疗结束后, 生化法检测小鼠血清中总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-c)、高密度脂蛋白胆固醇(HDL-c)和肝脏、粪便中TC水平; ELISA法检测小鼠血清肿瘤坏死因子α(TNF-α)、白介素6(IL-6)、白介素1β(IL-1β)水平; 肝脏HE和油红O染色观察小鼠肝脏脂质损伤; 生化法检测小鼠肝脏、血清、胆囊和粪便中总胆汁酸(TBA)含量; 液相质谱联用技术(UPLC-MS)对小鼠肝脏和粪便胆汁酸组分定量分析; 16S rRNA测序分析小鼠结肠菌群, 并分析粪便胆汁酸组分和肠道菌群之间的相关性。 结果 六味地黄方可以降低模型小鼠血清TC、TG、LDL-c以及TNF-α、IL-1β、IL-6水平(P < 0.01), 提高HDL-c水平(P < 0.01);并减少肝脏脂质堆积, 减轻肝脏损伤; 还可降低血清、胆囊和肝脏TBA水平(P < 0.01), 增加粪便中TBA排出(P < 0.01);减少粪便TαMCA、TβMCA、TCA、TCDCA、TDCA和CA结合型胆汁酸的含量(P < 0.05, P < 0.01), 增加次级胆汁酸LCA的含量(P < 0.01)。六味地黄方恢复了模型小鼠结肠菌群的平衡, 上调粪异杆菌属(Allobaculum)的相对丰度(P < 0.01), 并下调颤螺菌属(Oscillospira)和普氏菌(Prevotella)的相对丰度(P < 0.05)。 结论 六味地黄方通过重塑结肠菌群的结构恢复菌群的平衡, 增加粪便中次级胆汁酸的排出以降低血清和肝脏中胆固醇沉积, 从而改善模型小鼠胆固醇代谢异常。 Abstract:OBJECTIVE To investigate the regulation of intestinal microbiota and bile acid metabolism by Liuwei Dihuang formula (LW) to ameliorate postmenopausal cholesterol metabolism abnormalities and its possible mechanism of action. METHODS APOE-/- mice with bilateral ovariectomy were given a high-fat diet to replicate the postmenopausal cholesterol abnormality model, 0.13 mg·kg-1 estrogen and 9.0 g·kg-1 LW were used for treatment. The levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c) in serum, TC in liver and feces were measured by biochemical methods. The levels of tumor necrosis factor α (TNF-α), interleukin-6 (IL-6) and interleukin-1β (IL-1β) in serum were measured by enzyme-linked immunoassay. The levels of total bile acids (TBA) in the liver, serum, gallbladder and feces were measured by biochemical methods. Hepatic lipid damage was observed by HE and oil red staining. Fecal bile acids were quantified by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS). 16S rRNA sequencing was used to analyze the colonic microbiota of mice. The correlation between postmenopausal fecal bile acid fractions and intestinal microbiota was analyzed. RESULTS LW reduced serum TC, TG, LDL-c as well as TNF-α, IL-1β, IL-6 levels (P < 0.01) and increased HDL-c level in models (P < 0.01). LW ameliorated liver injury and reduced liver lipid accumulation. LW also reduced serum, gallbladder and hepatic TBA levels (P < 0.01) and increased fecal TBA excretion (P < 0.01); it also reduced fecal levels of conjugated bile acids such as TαMCA, TβMCA, TCA, TCDCA, TDCA and CA(P < 0.05, P < 0.01) and increased the level of secondary bile acid LCA (P < 0.01). LW restored the balance of colonic microbiota in model mice, upregulated the relative abundance of Allobaculum (P < 0.01), and downregulated the relative abundance of Oscillospira and Prevotella (P < 0.05). CONCLUSION LW ameliorates the cholesterol abnormalities in model mice by reshaping the composition of the colonic microbiota to restore the balance of the microbiota and increasing the excretion of fecal secondary bile acids to reduce cholesterol deposition in the serum and liver. -
Key words:
- Liuwei Dihuang formula /
- postmenopausal /
- APOE-/- mice /
- cholesterol metabolism /
- bile acids /
- intestinal microbiota
-
图 2 六味地黄方对绝经后APOE-/-小鼠肝脏胆固醇和胆汁酸堆积的影响
注: A.肝脏HE和油红O染色图,比例尺=50 μm;B.HE染色评价病理损伤面积百分比的定量分析图;C.油红O染色阳性面积百分比的定量分析图; D~E.肝脏TC和TBA含量图;F.肝脏差异胆汁酸含量图; C57+ND.正常对照组; APOE-/-+OVX+HFD.
模型组; APOE-/-+OVX+HFD+E2.雌二醇治疗组; APOE-/-+OVX+HFD+LW.六味地黄方治疗组; 与正常对照组比较, #P < 0.05, ##P < 0.01;与模型组比较, *P < 0.05, * *P < 0.01。x±s, n=5~6。Figure 2. Effect of LW on hepatic cholesterol and bile acid accumulation in postmenopausal APOE-/- mice
图 3 六味地黄方对绝经后APOE-/-小鼠的粪便胆固醇和胆汁酸排泄的影响
注: C57+ND.正常对照组; APOE-/-+OVX+HFD.模型组; APOE-/-+OVX+HFD+E2.雌二醇治疗组; APOE-/-+OVX+HFD+LW.六味地黄方治疗组; 与正常对照组比较, #P < 0.05, ##P < 0.01;与模型组比较, * *P < 0.05, * *P < 0.01。x±s, n=5~6。
Figure 3. Effect of LW on fecal cholesterol and bile acid excretion in postmenopausal APOE-/- mice
图 4 六味地黄方对绝经后APOE-/-小鼠肠道菌群组成的影响
注: A.物种多样性韦恩图;B.物种多样性PCoA聚类图;C.门水平差异物种丰度图; D.属水平益生菌、致病菌与其他菌组成图;E~H.
属水平差异物种丰度图。C57+ND.正常对照组; APOE-/-+OVX+HFD.模型组; APOE-/-+OVX+HFD+E2.雌二醇治疗组; APOE-/-+OVX+HFD+LW.六味地黄方治疗组; 与正常对照组比较, ##P < 0.01;与模型组比较, *P < 0.05, * *P < 0.01。x±s, n=5。Figure 4. Effects of LW on intestinal microbial composition in postmenopausal APOE-/- mice
-
[1] MEHTA LS, VELARDE GP, LEWEY J, et al. Cardiovascular disease risk factors in women: The impact of race and ethnicity: A scientific statement from the American heart association[J]. Circulation, 2023, 147(19): 1471-1487. doi: 10.1161/CIR.0000000000001139 [2] ROHIRA AD, LONARD DM, O'MALLEY BW. Emerging roles of steroid receptor coactivators in stromal cell responses[J]. J Endocrinol, 2021, 248(2): R41-R50. doi: 10.1530/JOE-20-0511 [3] SCHWARTZ GN, KAUFMAN PA, GIRIDHAR KV, et al. Alternating 17β-estradiol and aromatase inhibitor therapies is efficacious in postmenopausal women with advanced endocrine-resistant ER+breast cancer[J]. Clin Cancer Res, 2023, 29(15): 2767-2773. doi: 10.1158/1078-0432.CCR-23-0112 [4] 肖微, 周俊, 章文春. 六味地黄方制剂治疗更年期综合征疗效的Meta分析[J]. 中国实验方剂学杂志, 2016, 22(4): 222-228. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX201604051.htmXIAO W, ZHOU J, ZHANG WC. Meta-analysis of Liuwei Dihuang prescription in treatment of menopausal syndrome[J]. Chin J Exp Tradit Med Formulae, 2016, 22(4): 222-228. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX201604051.htm [5] CHEN Q, QI X, FU Y, et al. Liuwei Dihuang formula protect endothelial cells from apoptosis by up-regulating expression of estrogen receptor-α[J]. J Tradit Chin Med Engl Ed, 2021, 41(2): 227-235. http://www.cnki.com.cn/Article/CJFDTotal-ZYYW202102006.htm [6] 孟庆海, 马猛华, 余夕潮, 等. 六味地黄方通过上调肠道雌激素受体改善绝经后ApoE-/-小鼠脂代谢异常研究[J]. 南京中医药大学学报, 2020, 36(5): 661-666, 674. http://xb.njucm.edu.cn/article/id/zr20200514MENG QH, MA MH, YU XC, et al. Liuwei Dihuang formula alleviates abnormal lipid metabolism by up-regulating intestinal estrogen receptors in postmenopausal ApoE-/- mice[J]. J Nanjing Univ Tradit Chin Med, 2020, 36(5): 661-666, 674. http://xb.njucm.edu.cn/article/id/zr20200514 [7] DE BOER JF, KUIPERS F, GROEN AK. Cholesterol transport revisited: A new turbo mechanism to drive cholesterol excretion[J]. Trends Endocrinol Metab, 2018, 29(2): 123-133. doi: 10.1016/j.tem.2017.11.006 [8] SANTOS-MARCOS JA, RANGEL-ZUÑIGA OA, JIMENEZ-LUCENA R, et al. Influence of gender and menopausal status on gut microbiota[J]. Maturitas, 2018, 116: 43-53. doi: 10.1016/j.maturitas.2018.07.008 [9] 孟庆海. 泽泻醇B乙酸酯通过调节肠道菌群和肠道雌激素受体抗绝经后动脉粥样硬化的机制研究[D]. 南京: 南京中医药大学, 2021.MENG QH. Mechanism of alisol B acetate in preventing postmenopausal atherosclerosis by regulating intestinal flora and estrogen receptor[D]. Nanjing: Nanjing University of Chinese Medicine, 2021. [10] CHEN Q, ZHANG YH, MENG QH, et al. Liuwei Dihuang prevents postmenopausal atherosclerosis and endothelial cell apoptosis via inhibiting DNMT1-medicated ERα methylation[J]. J Ethnopharmacol, 2020, 252: 112531. doi: 10.1016/j.jep.2019.112531 [11] 居玲玲, 文红梅, 马昕, 等. 固相萃取HPLC法研究六昧地黄方中马钱素和莫罗苷的血药浓度及配伍变化[J]. 中药新药与临床药理, 2008, 19(3): 206-209. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXY200803016.htmJU LL, WEN HM, MA X, et al. Study on loganin and morronside concentrations in rat serum containing Liuwei Dihuang formula by SPE-HPLC and the variety of different combinations[J]. Tradit Chin Drug Res Clin Pharmacol, 2008, 19(3): 206-209. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXY200803016.htm [12] 姚远, 吴艳, 马志, 等. 六味地黄方及配伍对去势雌性大鼠动脉粥样硬化模型的作用[J]. 中成药, 2016, 38(10): 2111-2117. https://www.cnki.com.cn/Article/CJFDTOTAL-ZCYA201610004.htmYAO Y, WU Y, MA Z, et al. Effect of Liuwei Dihuang Formula and its compatibility on rats with ovariectomy-induced atherosclerosis[J]. Chin Tradit Pat Med, 2016, 38(10): 2111-2117. https://www.cnki.com.cn/Article/CJFDTOTAL-ZCYA201610004.htm [13] ZHENG XJ, CHEN TL, ZHAO AH, et al. Hyocholic acid species as novel biomarkers for metabolic disorders[J]. Nat Commun, 2021, 12(1): 1487. doi: 10.1038/s41467-021-21744-w [14] LI MC, WANG SL, LI YT, et al. Gut microbiota-bile acid crosstalk contributes to the rebound weight gain after calorie restriction in mice[J]. Nat Commun, 2022, 13(1): 2060. doi: 10.1038/s41467-022-29589-7 [15] WOODWARD A, BROOM D, DALTON C, et al. Supervised exercise training and increased physical activity to reduce cardiovascular disease risk in women with polycystic ovary syndrome: Study protocol for a randomized controlled feasibility trial[J]. Trials, 2020, 21(1): 101. doi: 10.1186/s13063-019-3962-7 [16] MENG QH, MA MH, ZHANG WW, et al. The gut microbiota during the progression of atherosclerosis in the perimenopausal period shows specific compositional changes and significant correlations with circulating lipid metabolites[J]. Gut Microbes, 2021, 13(1): 1-27. [17] 马猛华. 基于肠道ERα/IAP/肠道菌群途径探讨六味地黄方抗绝经后动脉粥样硬化作用及机制[D]. 南京: 南京中医药大学, 2021.MA MH. Based on the intestinal ERα/IAP/intestinal flora pathway, the anti-atherosclerosis effect and mechanism of Liuwei Dihuang recipe were discussed[D]. Nanjing: Nanjing University of Chinese Medicine, 2021. [18] JIA W, XIE GX, JIA WP. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(2): 111-128. doi: 10.1038/nrgastro.2017.119 [19] 王佩文. 围绝经期冠心病患者总胆汁酸、胆固醇的变化及相关性[D]. 郑州: 郑州大学, 2019.WANG PW. Changes and correlation of total bile acids and cholesterol in perimenopausal patients with coronary heart disease[D]. Zhengzhou: Zhengzhou University, 2019. [20] ALEMÁN JO, BOKULICH NA, SWANN JR, et al. Fecal microbiota and bile acid interactions with systemic and adipose tissue metabolism in diet-induced weight loss of obese postmenopausal women[J]. J Transl Med, 2018, 16(1): 244. doi: 10.1186/s12967-018-1619-z [21] TAYLOR SA, GREEN RM. Bile acids, microbiota, and metabolism[J]. Hepatology, 2018, 68(4): 1229-1231. doi: 10.1002/hep.30078 [22] QIAO SS, LIU C, SUN L, et al. Gut Parabacteroides merdae protects against cardiovascular damage by enhancing branched-chain amino acid catabolism[J]. Nat Metab, 2022, 4(10): 1271-1286. doi: 10.1038/s42255-022-00649-y [23] CHAKAROUN RM, OLSSON LM, BÄCKHED F. The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease[J]. Nat Rev Cardiol, 2023, 20(4): 217-235. doi: 10.1038/s41569-022-00771-0 [24] ZHAO H, CHEN JJ, LI XP, et al. Compositional and functional features of the female premenopausal and postmenopausal gut microbiota[J]. FEBS Lett, 2019, 593(18): 2655-2664. doi: 10.1002/1873-3468.13527 [25] DUAN MM, WANG YZ, ZHANG Q, et al. Characteristics of gut microbiota in people with obesity[J]. PLoS One, 2021, 16(8): e0255446. doi: 10.1371/journal.pone.0255446 [26] FUNABASHI M, GROVE TL, WANG M, et al. A metabolic pathway for bile acid dehydroxylation by the gut microbiome[J]. Nature, 2020, 582(7813): 566-570. doi: 10.1038/s41586-020-2396-4 [27] MATSON V, CHERVIN CS, GAJEWSKI TF. Cancer and the microbiome-influence of the commensal microbiota on cancer, immune responses, and immunotherapy[J]. Gastroenterology, 2021, 160(2): 600-613.